Biotechnology - Licensing, China

Filter

Current filters:

LicensingChina

Popular Filters

3SBio gains exclusive license for PharmAbcine’s tanibirumab

20-11-2014

Chinese biotech firm 3SBio Inc has entered into an exclusive license with PharmAbcine for the development,…

3SBioBiotechnologyBrazilChinaLicensingOncologyPharmAbcineRussiatanibirumabThailand

WuXi PharmaTech collaborates on genomic profiling for China

24-10-2014

China’s WuXi PharmaTech has entered into a collaboration with USA-based Foundation Medicine to offer…

BiotechnologyChinaFoundation MedicineLicensingOncologyWuXi PharmaTech

TNI BioTech and Hubei Qianjiang link up on cancer drug development

TNI BioTech and Hubei Qianjiang link up on cancer drug development

13-08-2014

US biotech firm TNI BioTech has signed a supplemental agreement with China’s Hubei Qianjiang Pharmaceutical…

BiotechnologyBusiness FinanceChinaHubeiLicensingOncologyQianjiang PharmaceuticalResearchTNI BioTechUSA

Ambrx and Zhejiang Hisun sign deal over cancer treatment

Ambrx and Zhejiang Hisun sign deal over cancer treatment

30-04-2014

USA-based clinical-stage biopharmaceutical company Ambrx and Chinese pharma firm Zhejiang Hisun Pharmaceutical…

AmbrxBiopharmaceuticalBiotechnologyBusiness FinanceChinaHealth Medical PharmaHealth Medical PharmaLicensingOncologyPharmaceutical industryUSA

Dutch biotech Mucosis partners with Chinese firm

Dutch biotech Mucosis partners with Chinese firm

15-04-2014

Dutch biotech company Mucosis has entered into a long-term collaboration and license agreement with China-based…

BiotechnologyChangchunChief executiveChinaDiseaseHuman respiratory syncytial virusLicensingMimopath technologyNetherlandsVaccines

Merck Serono signs $232 million deal with Chinese company for BeiGene-290

Merck Serono signs $232 million deal with Chinese company for BeiGene-290

13-11-2013

Merck Serono has signed a global licensing, co-development and commercialization agreement for BeiGene-290…

Asia-PacificBeiGeneBiotechnologyChinaLicensingMerck SeronoOncology

Back to top